Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells

Fig. 5

DMA-alantolactone inhibited tumor growth effectively in vivo. a Synthesis of the pro-drug of alantolactone, i.e., DMA-alantolactone. b The body weight of the mice after the oral administration of alantolactone at a dose of 500 mg/kg. c KG1a cells were injected into 5-week-old female BALB/c nude mice. After 20 days, tumor was cut to the same volume (0.5 mm3). The small tumor pieces were implanted into mice. When tumor volume reached to 100 mm3, DMA-alantolactone was administrated by oral every 3 days with 100 mg/kg. Mice were sacrificed after 30 days. *P < 0.05, **P < 0.01, ***P < 0.0001

Back to article page